Quantum BioPharma is trading at $2.95, down 5.14%, with no direct catalyst established in available reporting. - No clear company-specific announcement on October 9 explains the decline; the Thermo Fisher trial-start agreement was announced earlier, on October 6. - The biotechnology sector was reported higher, and broad market indices were also up in the supplied context, so those trends do not explain the stock’s decline.